{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:51:47Z","timestamp":1773406307350,"version":"3.50.1"},"reference-count":67,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MECONC\/ 29043\/2017"],"award-info":[{"award-number":["PTDC\/MECONC\/ 29043\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/132751\/2017"],"award-info":[{"award-number":["SFRH\/BD\/132751\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The immune infiltrate plays an important part in testicular germ cell tumors, but it remains scarcely studied. We aimed at thoroughly characterizing the immune infiltrate and expression of immune checkpoints PD-L1\/CTLA-4 and mismatch repair (MMR) proteins in these neoplasms, seeking for associations with patient outcome. Methods: A total of 162 consecutively diagnosed patients (2005\u20132018) were included. Immunostaining for PD-L1, CTLA-4 and MMR proteins was independently assessed both in immune cells (ICs) and tumor cells (TCs) of primary tumors and metastases, and characterization of IC populations was pursued. Results: PD-L1 and CTLA-4 positivity in ICs was frequent (85.5% and 96.3%). Patients with absent PD-L1 positive ICs exhibited significantly worse relapse-free survival (hazard ratio = 4.481, 95% CI 1.366\u201314.697, p = 0.013), both in univariable and multivariable analysis. Lower CD20 and CD3 IC infiltration in seminomas associated with higher disease stage (p = 0.0216, p = 0.0291). CTLA-4 TC intensity was significantly higher in yolk sac tumor, choriocarcinoma and teratoma, while PD-L1 TC positivity was significantly more frequent in choriocarcinoma. Both PD-L1 and CTLA-4 immunoexpression in ICs of metastatic samples was frequent (100% and 88.2%). MMR proteins were differentially expressed among the different tumor subtypes. Conclusions: Immune infiltrate\/checkpoints associate with patients\u2019 outcome, constituting novel (potentially targetable) disease biomarkers.<\/jats:p>","DOI":"10.3390\/cancers11101535","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T10:53:03Z","timestamp":1570791183000},"page":"1535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1\/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"first","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"given":"\u00c2ngelo","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"given":"Rita","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Mariana","family":"Cantante","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Paula","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Joaquina","family":"Maur\u00edcio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Urology Clinic, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Urology &amp; Urology Clinic, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (GEBC CI-IPOP) and Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ucl.2015.04.001","article-title":"Epidemiology and Diagnosis of Testis Cancer","volume":"42","author":"Stevenson","year":"2015","journal-title":"Urol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/andr.12611","article-title":"Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors-past, present, and future considerations","volume":"7","author":"Oing","year":"2019","journal-title":"Andrology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ucl.2015.04.010","article-title":"Late Relapse of Testicular Germ Cell Tumors","volume":"42","author":"Feldman","year":"2015","journal-title":"Urol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.urolonc.2015.05.002","article-title":"Secondary malignant neoplasms in testicular cancer survivors","volume":"33","author":"Curreri","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ucl.2015.05.003","article-title":"Infertility with Testicular Cancer","volume":"42","author":"Ostrowski","year":"2015","journal-title":"Urol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3389\/fonc.2018.00571","article-title":"Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice","volume":"8","author":"Chovanec","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., Jeronimo, C., Henrique, R., and Looijenga, L.H.J. (2019). Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020258"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/epi-2016-0081","article-title":"The epigenetics of testicular germ cell tumors: Looking for novel disease biomarkers","volume":"9","author":"Costa","year":"2017","journal-title":"Epigenomics"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Moch, H., Ulbright, T., Humphrey, P., and Reuter, V. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs, IARC. [4th ed.].","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pathol.2017.07.013","article-title":"Pitfalls in the interpretation of specimens from patients with testicular tumours, with an emphasis on variant morphologies","volume":"50","author":"Ulbright","year":"2018","journal-title":"Pathology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.path.2015.07.007","article-title":"Tumors of the Testis: Morphologic Features and Molecular Alterations","volume":"8","author":"Howitt","year":"2015","journal-title":"Surg. Pathol. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0893-3952(22)04459-3","article-title":"Germ cell tumors of the gonads: A selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues","volume":"18","author":"Ulbright","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_13","first-page":"rjy358","article-title":"Spontaneous regression as a \u2018burned-out\u2019 non-seminomatous testicular germ cell tumor: A case report and literature review","volume":"2019","year":"2019","journal-title":"J. Surg. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2016.06.012","article-title":"Immunotherapy advances in uro-genital malignancies","volume":"105","author":"Ratta","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1305535","DOI":"10.1080\/2162402X.2017.1305535","article-title":"Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling","volume":"6","author":"Siska","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/2326-6066.CIR-16-0087","article-title":"Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors","volume":"4","author":"Shah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21794","DOI":"10.18632\/oncotarget.15585","article-title":"Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors","volume":"8","author":"Chovanec","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","first-page":"1497","article-title":"Expression of the immune checkpoint receptor TIGIT in seminoma","volume":"18","author":"Hinsch","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1172\/JCI127726","article-title":"The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy","volume":"129","author":"Wei","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1016\/j.clgc.2017.04.005","article-title":"Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor","volume":"15","author":"Chi","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000783","article-title":"PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors","volume":"41","author":"Sloan","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2016.95","article-title":"PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes","volume":"29","author":"Rosenbaum","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2008.18.8623","article-title":"Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors","volume":"27","author":"Honecker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13402-017-0326-8","article-title":"Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours","volume":"40","author":"Rudolph","year":"2017","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","article-title":"Testicular germ cell tumors: Revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists","volume":"82","author":"Lobo","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1060028017727546","article-title":"The Emerging Role of PD-1\/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma","volume":"52","author":"Gwynn","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/SPC.0000000000000363","article-title":"Role of immunotherapy in kidney cancer","volume":"12","author":"Nazzani","year":"2018","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-10-2232","article-title":"Cytotoxic T-lymphocyte-associated antigen-4","volume":"17","author":"Salama","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing signals: Recent progress in CTLA-4 biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF01606913","article-title":"Immunohistological analysis of tumour infiltrating lymphocytes in seminoma using monoclonal antibodies","volume":"421","author":"Nakanoma","year":"1992","journal-title":"Virchows Arch. A"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2559.1997.d01-560.x","article-title":"Quantification of immunocompetent cells in testicular germ cell tumours","volume":"30","author":"Torres","year":"1997","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s002400000143","article-title":"Expression of MAGE antigens and analysis of the inflammatory T-cell infiltrate in human seminoma","volume":"28","author":"Grobholz","year":"2000","journal-title":"Urol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/path.996","article-title":"Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma","volume":"196","author":"Yakirevich","year":"2002","journal-title":"J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jri.2013.10.005","article-title":"Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia","volume":"100","author":"Hvarness","year":"2013","journal-title":"J. Reprod. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/humrep\/dew211","article-title":"Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia","volume":"31","author":"Klein","year":"2016","journal-title":"Hum. Reprod."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fendo.2017.00307","article-title":"Cytokines in Male Fertility and Reproductive Pathologies: Immunoregulation and Beyond","volume":"8","author":"Loveland","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ijc.21894","article-title":"Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells","volume":"119","author":"Hadrup","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4132\/jptm.2019.04.24","article-title":"PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future","volume":"53","author":"Kim","year":"2019","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1084\/jem.20050019","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00262-017-2039-2","article-title":"CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: Diverging prognostic impact in primary tumors and lymph node metastases","volume":"66","author":"Paulsen","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/molehr\/5.1.84","article-title":"The CTLA-4 gene is expressed in placental fibroblasts","volume":"5","author":"Kaufman","year":"1999","journal-title":"Mol. Hum. Reprod."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2018.09.010","article-title":"An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis","volume":"75","author":"Necchi","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_51","first-page":"4319","article-title":"Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors","volume":"25","author":"Olasz","year":"2005","journal-title":"Anticancer. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lobo, J., Pinto, C., Pinheiro, M., Lobo, F., Sousa, N., Lopes, P., Looijenga, L.H.J., Jeronimo, C., Teixeira, M.R., and Henrique, R. (2019). Widening the spectrum of Lynch syndrome: First report of testicular seminoma attributable to MSH2 loss. Histopathology.","DOI":"10.1111\/his.13979"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.celrep.2018.05.039","article-title":"Integrated Molecular Characterization of Testicular Germ Cell Tumors","volume":"23","author":"Shen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4161\/cbt.3.10.1135","article-title":"Mismatch repair gene expression and genetic instability in testicular germ cell tumor","volume":"3","author":"Velasco","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"75379","DOI":"10.18632\/oncotarget.12211","article-title":"Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix","volume":"7","author":"Rieke","year":"2016","journal-title":"Oncotarget"},{"key":"ref_56","unstructured":"Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_57","unstructured":"(2019, July 01). International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. Available online: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.1997.15.2.594."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00432-019-02844-z","article-title":"Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment","volume":"145","author":"Fankhauser","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12967-019-1837-z","article-title":"m(6)A RNA modification and its writer\/reader VIRMA\/YTHDF3 in testicular germ cell tumors: A role in seminoma phenotype maintenance","volume":"17","author":"Lobo","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2217\/epi-2018-0034","article-title":"DNA methylation profiling as a tool for testicular germ cell tumors subtyping","volume":"10","author":"Costa","year":"2018","journal-title":"Epigenomics"},{"key":"ref_61","first-page":"20170388","article-title":"Germ cell tumour subtypes display differential expression of microRNA371a-3p","volume":"373","author":"Lobo","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1758835918763493","DOI":"10.1177\/1758835918763493","article-title":"PD-L1 expression testing in non-small cell lung cancer","volume":"10","author":"Teixido","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/PAS.0000000000001084","article-title":"PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma","volume":"42","author":"Hodgson","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lobo, J., Henrique, R., and Jeronimo, C. (2018). The Role of DNA\/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors. Cancers, 11.","DOI":"10.3390\/cancers11010006"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41585-019-0154-x","article-title":"Epigenetic drugs and their molecular targets in testicular germ cell tumours","volume":"16","author":"Jostes","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3718165","DOI":"10.1155\/2018\/3718165","article-title":"Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors","volume":"2018","author":"Chovanec","year":"2018","journal-title":"Adv. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/fon-2018-0571","article-title":"Immunotherapy: Last bullet in platinum refractory germ cell testicular cancer","volume":"15","author":"Semaan","year":"2019","journal-title":"Future Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/10\/1535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:10Z","timestamp":1760189110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/10\/1535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["cancers11101535"],"URL":"https:\/\/doi.org\/10.3390\/cancers11101535","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]}}}